(Q37920741)

25 August 2017

1 reference

title

Targeted and multifunctional arene ruthenium chemotherapeutics (English)

1 reference

25 August 2017

1 reference

1 reference

Gregory S Smith

1

0 references

Bruno Therrien

series ordinal

2

object named as

Bruno Therrien

1 reference

PubMed ID

21858344

25 August 2017

language of work or name

English

0 references

publication date

22 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

40

1 reference

25 August 2017

10793-10800

1 reference

25 August 2017

41

1 reference

Ruthenium(II) metallo-intercalators: DNA imaging and cytotoxicity

25 August 2017

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Arene ruthenium complexes as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Unusual DNA binding modes for metal anticancer complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Recent developments in ruthenium anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Ruthenium Anticancer Compounds: Challenges and Expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Metal-based antitumour drugs in the post-genomic era: what comes next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Organometallic anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Transition metal based anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Developing new metal-based therapeutics: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Rational design of an organometallic glutathione transferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Switching on a signaling pathway with an organoruthenium complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Inert ruthenium half-sandwich complexes with anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

(Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Ligand-based neutral ruthenium(II) arene complex: selective anticancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Boron neutron capture therapy at the crossroads: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Hyperthermia adds to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Use of perfluorinated phosphines to provide thermomorphic anticancer complexes for heat-based tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

A novel ruthenium(II) arene based intercalator with potent anticancer activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Carbohydrate-metal complexes and their potential as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Modifying the structure of dinuclear ruthenium complexes with antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Control of tumour vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Anticancer activity of tetracationic arene ruthenium metalla-cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Tetranuclear coordination assemblies based on half-sandwich ruthenium(II) complexes: noncovalent binding to DNA and cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Anticancer activity of opened arene ruthenium metalla-assemblies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Evidence for drug release from a metalla-cage delivery vector following cellular internalisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

The role of porphyrin chemistry in tumor imaging and photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Modulation of photosensitization processes for an improved targeted photodynamic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Future of oncologic photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

A fluorinated ruthenium porphyrin as a potential photodynamic therapy agent: synthesis, characterization, DNA binding, and melanoma cell studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

An amphiphilic ruthenium(II)-polypyridyl appended porphyrin as potential bifunctional two-photon tumor-imaging and photodynamic therapeutic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

DNA binding and photocleavage properties and apoptosis-inducing activities of a ruthenium porphyrin complex [(Py-3')TPP-Ru(phen)2Cl]Cl and its heterometallic derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Ruthenium porphyrin compounds for photodynamic therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Structure and biodistribution relationships of photodynamic sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1DT11007A

21 January 2018

Identifiers

DOI

10.1039/C1DT11007A

1 reference

25 August 2017

1 reference

PubMed ID

21858344